| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/27/2003 | WO2003016279A1 Fused-polycyclic compounds |
| 02/27/2003 | WO2003016277A1 Cyclohept`b!indole derivatives as spla2 inhibitors |
| 02/27/2003 | WO2003016276A2 3-substituted oxindole beta-3 agonists |
| 02/27/2003 | WO2003016275A1 Antiviral agent |
| 02/27/2003 | WO2003016273A2 Peptide arginals and methods for treating disseminated intravascular coagulation |
| 02/27/2003 | WO2003016270A2 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003016267A1 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| 02/27/2003 | WO2003016261A1 Substituted octahydrophenanthrene compounds and their use as nmda antagonists |
| 02/27/2003 | WO2003015872A2 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders |
| 02/27/2003 | WO2003015831A1 Gas microsphere liposome composites |
| 02/27/2003 | WO2003015830A1 Theurapeutic tropane compounds |
| 02/27/2003 | WO2003015827A1 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 02/27/2003 | WO2003015825A2 Conjugate |
| 02/27/2003 | WO2003015822A1 5-cnac as oral delivery agent for parathyroid hormone fragments |
| 02/27/2003 | WO2003015820A1 GnRH AGONIST COMBINATION DRUGS |
| 02/27/2003 | WO2003015811A1 Process for obtaining a pharmaceutical composition |
| 02/27/2003 | WO2003015809A2 Antimicrobial cationic peptides and formulations thereof |
| 02/27/2003 | WO2003015807A1 Side effct-relieving agents and/or hypoglycemic effect enhancers for thiazolidine derivatives |
| 02/27/2003 | WO2003015805A1 Composition for removal of toxins |
| 02/27/2003 | WO2003015799A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | WO2003015798A1 Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue |
| 02/27/2003 | WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | WO2003015795A1 Physiological method of improving vision |
| 02/27/2003 | WO2003015794A1 Methods and compositions for treating apoptosis associated disorders |
| 02/27/2003 | WO2003015793A1 Delayed and sustained drug release |
| 02/27/2003 | WO2003015792A1 Anti-tumour 2-alkoxyestradiol sulfamates |
| 02/27/2003 | WO2003015791A1 Phophylactic and therapeutic use of hydroxysteroids |
| 02/27/2003 | WO2003015790A1 Thiopyrane-4-ones as dna protein kinase inhibitors |
| 02/27/2003 | WO2003015789A2 A pharmaceutical composition for dermal application |
| 02/27/2003 | WO2003015788A1 Methods for treatment of prevention of cancer or neoplastic diseases |
| 02/27/2003 | WO2003015787A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 02/27/2003 | WO2003015785A1 2h-phthalazin-1-ones and methods for use thereof |
| 02/27/2003 | WO2003015784A1 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors |
| 02/27/2003 | WO2003015783A1 Method of treating alcoholism or alcohol abuse |
| 02/27/2003 | WO2003015782A2 Receptor-adapted nicotine withdrawal by anti-cholinergic and anti-noradrenergic blockage |
| 02/27/2003 | WO2003015781A1 Novel antidiabetic pharmaceutical compositions |
| 02/27/2003 | WO2003015780A2 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease |
| 02/27/2003 | WO2003015778A1 Tyrosine kinase inhibitors |
| 02/27/2003 | WO2003015776A1 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| 02/27/2003 | WO2003015775A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels |
| 02/27/2003 | WO2003015774A1 Compounds effecting glucokinase |
| 02/27/2003 | WO2003015773A2 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases |
| 02/27/2003 | WO2003015772A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | WO2003015770A1 Novel combination |
| 02/27/2003 | WO2003015769A1 Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments |
| 02/27/2003 | WO2003015768A2 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| 02/27/2003 | WO2003015767A2 Use of tectorigenin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin |
| 02/27/2003 | WO2003015766A1 Use of wogonin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin |
| 02/27/2003 | WO2003015765A1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect |
| 02/27/2003 | WO2003015764A1 Rapid growth dairy heifers having reduced mammary fat content |
| 02/27/2003 | WO2003015763A1 Adjuvant chemotherapy for anaplastic gliomas |
| 02/27/2003 | WO2003015762A1 Remedial agent for cardiac failure |
| 02/27/2003 | WO2003015761A1 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003015760A1 Use of dmso in the treatment of neurodegenerative diseases caused by prions |
| 02/27/2003 | WO2003015759A2 Treatment of hyperproliferative conditions of body surfaces |
| 02/27/2003 | WO2003015758A1 Sustained release micropellets and process for producing the same |
| 02/27/2003 | WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 02/27/2003 | WO2003015755A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 02/27/2003 | WO2003015752A1 The process for preparing isotonic topical antibiotic ophthalmic formulation with improved therapeutic effect |
| 02/27/2003 | WO2003015751A1 Pharmaceutical composition for nasal delivery of estradiol and norethisterone |
| 02/27/2003 | WO2003015748A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | WO2003015745A1 Expandable gastric retention device |
| 02/27/2003 | WO2003015744A1 Chitin microparticles and their medical uses |
| 02/27/2003 | WO2003015741A1 Humectant and cosmetics and external preparations containing the same |
| 02/27/2003 | WO2003015738A1 Active ingredient mixtures |
| 02/27/2003 | WO2003015737A1 Use of oroxylin a for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and/or for skin protection of determinate sensitive and dry skin |
| 02/27/2003 | WO2003015729A1 Topical composition for follicular delivery of an ornithine decarboxylase inhibitor |
| 02/27/2003 | WO2003015717A2 Tyrosine kinase inhibitors |
| 02/27/2003 | WO2003015713A2 Treatment of glial tumors with glutamate antagonists |
| 02/27/2003 | WO2003015711A2 Combination motif immune stimulatory oligonucleotides with improved activity |
| 02/27/2003 | WO2003015707A2 Method for treating lung cancers |
| 02/27/2003 | WO2003015706A2 Borinic acid protease inhibitors |
| 02/27/2003 | WO2003015704A2 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 02/27/2003 | WO2003015703A2 Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| 02/27/2003 | WO2003015700A2 Novel vasoconstrictor cannabinoid analogs |
| 02/27/2003 | WO2003015699A2 Topical compositions and methods for treating pain |
| 02/27/2003 | WO2003015695A2 Canine cardiac diet |
| 02/27/2003 | WO2003015693A2 Screening and therapeutic methods for promoting wakefulness and sleep |
| 02/27/2003 | WO2003015690A2 Method for treating primary insomnia |
| 02/27/2003 | WO2003015689A2 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 02/27/2003 | WO2003015678A1 Composition and transdermal drug delivery device |
| 02/27/2003 | WO2003015614A2 Use of clc3 chloride channel blockers to modulate vascular tone |
| 02/27/2003 | WO2003015608A2 Combination therapy for the treatment of cancer |
| 02/27/2003 | WO2003015606A2 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
| 02/27/2003 | WO2003015605A2 Use of s-nitrosothiol signaling to treat disordered control of breathing |
| 02/27/2003 | WO2003015521A1 Treatment of cancers by inhalation of stable platinum-containing formulations |
| 02/27/2003 | WO2003015517A1 Agonists and antagonists of 5h3-like receptors of invertebrate s as pesticides |
| 02/27/2003 | WO2003015516A1 Compositions and methods for treatment of mitochondrial diseases |
| 02/27/2003 | WO2003015494A2 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | WO2003004098A8 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 02/27/2003 | WO2003002123A3 Therapeutic combinations for the treatment of hormone deficiencies |
| 02/27/2003 | WO2003001881A3 Cell-based high-throughput screening methods |
| 02/27/2003 | WO2003000656A3 Antisense modulation of transforming growth factor beta receptor ii expression |
| 02/27/2003 | WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/27/2003 | WO2002103000A3 Methods for modulating gap junctions |
| 02/27/2003 | WO2002102988A3 Method for neural stem cell differentiation using 5ht-1a agonists |
| 02/27/2003 | WO2002102777A3 NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE |
| 02/27/2003 | WO2002100862A3 Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine |
| 02/27/2003 | WO2002100851A3 Thiophene derivatives as antiviral agents for flavivirus infection |
| 02/27/2003 | WO2002100348A3 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |